People · Operator
Named in public records as an officer, director or promoter · active 2020–2020 · Pharmaceuticals
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Primmune Therapeutics, Inc. | — | Pharmaceuticals | Series A | $20.1M | $350.3M | 2020 |
Andrew S. Rubinstein at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Andrew S. Rubinstein on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Charles McDermott | 1 | 8 |
| AMIR S. NASHAT | 1 | 3 |
| Scott S. Morenstein | 1 | 3 |
| James R. Appleman | 1 | 1 |
| Todd J. Harris | 1 | 1 |
| Paulo S. Rangel | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.